CA-C3-AI
16.2.2021 22:29:13 CET | Business Wire | Press release
C3 AI (NYSE:AI), a leading enterprise AI software provider, today announced the release of major enhancements to its enterprise AI application development platform and AI applications designed to further accelerate digital transformation. Over the past decade, C3 AI has invested continuously in the C3 AI® Suite, its open, secure, and multi-cloud enterprise AI platform that leverages a model-driven architecture, enabling end-to-end enterprise AI including data integration, model development, MLOps, application development, and model governance and maintenance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210216006166/en/
The latest release – Version 7.17 – provides new capabilities to track and manage full lineage from data sources to application entities. In addition, the latest release includes new composable machine learning (ML) pipelines for data scientists; enhancements to C3 AI CRM, C3 AI Anti-Money Laundering, C3 AI Energy Management, C3 AI Production Schedule Optimization, and C3 AI Reliability applications; and a new enterprise AI application for the oil and gas industry, C3 AI Well Development Optimization.
“Today’s release introduces even more market-leading features for developers, data scientists, and data engineers, while bringing unparalleled speed to the development of enterprise AI applications,” said C3 AI President and Chief Product Officer Houman Behzadi. “We continue to invest significantly in our enterprise AI platform, wide range of developer tools, and configurable enterprise AI applications to enable a richer and more cohesive developer and user experience to accelerate AI adoption.”
The latest platform enhancements and features available with the C3 AI Suite include:
- Comprehensive data, feature, and model lineage: Improvements to enterprise AI application development tools include a new comprehensive data, feature, and model lineage component that enables developers and end users to understand the lineage of their application and AI/ML results.
- Enhanced time series feature generation: The latest release significantly accelerates feature engineering and model development. Enhancements enable faster feature parameterization, more comprehensive statistical transformations, and improved feature selection for use in C3 AI ML Pipelines.
- New composable ML pipelines: Expanding the ever-growing library of C3 AI ML Pipelines, the latest release includes four new pipelines to accelerate model development, including a deep learning pipe for forecasting and a linear quantile regression pipe for probabilistic predictions. C3 AI ML Pipelines also deliver improved model interpretability support with the addition of SHAP (Shapley Additive Explanations) to the available explainability frameworks.
- Multi-cloud Kubernetes service: As part of the ongoing Kubernetes/OpenShift standardization, the latest release supports the Kubernetes service on all clouds.
- New prebuilt data connectors: Performance and scalability improvements to C3 AI’s Virtual Data Lake framework include connectors to Snowflake, Spark/Databricks, S3, Microsoft Power BI, Azure Data Lake, and Microsoft Dynamics 365 – further expanding the library of prebuilt data connectors on the C3 AI Suite. The new connectors help accelerate data integration and allow engineers to create a virtual data image or ingest data directly into the C3 AI Suite.
- Enhancements to enterprise object models: New additions and enhancements to C3 AI’s suite of prebuilt enterprise object models further accelerate development of AI applications. Cross-industry object models provide functional capabilities, including energy management, equipment and process reliability, fraud detection, inventory optimization, and manufacturing yield optimization. In addition, C3 AI also offers industry-specific object models for manufacturing, financial services, oil and gas, utilities, and defense.
C3 AI also continues to invest in its growing portfolio of enterprise AI applications. Notable enhancements include:
- C3 AI CRM delivers a new AI-based precision revenue forecasting and opportunity scoring feature leveraging both data in traditional CRM systems and external feeds (e.g., financial data, news, commodity prices).
- C3 AI Reliability enhancements include a new module – C3 AI Diagram Parsing – to automatically generate digital twins and object models from piping and instrumentation diagrams (P&IDs). C3 AI Diagram Parsing uses machine vision and natural language processing to parse P&IDs to generate machine-readable asset hierarchies and sensor-to-asset mappings.
- C3 AI Inventory Optimization enhancements include what-if scenario modeling capabilities for inventory analysts to account for the ever-changing dynamics of globally distributed supply chains and optimize for the best operating outcomes.
- C3 AI Production Schedule Optimization enhancements include a new user interface, enhancements to the object model, and additional composable ML pipelines. Modifications to the user interface enable end users to more easily generate, review, and act on AI-based demand forecasts and order line recommendations. The newly available demand planning and scheduling data models and ML pipelines help accelerate model development and deployment for data science teams.
- C3 AI Well Development Optimization is a new oil and gas application that optimizes upstream drilling costs and mitigates non-productive time risks such as stuck pipe, lost circulation, and drilling recovery. The application provides the foundational data model for AI-enabled well development applications, as well as for upstream oil and gas operators to plan and execute drilling operations.
For more information about this new release, please contact sales@c3.ai .
About C3.ai, Inc.
C3.ai, Inc. (NYSE:AI) is a leading provider of enterprise AI software for accelerating digital transformation. C3 AI delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216006166/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom